Compare Novartis AG (NVS) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Ferrari NV — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Ferrari NV trades at $406.75 (market cap $71.67B). The key difference: Novartis AG is far larger — about 4.2× Ferrari NV's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| NVS | RACE | |
|---|---|---|
Market Cap | $298.18B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $504.09 |
52-Week Low | $119.31 | $314.63 |
Enterprise Value | $339.50B | $73.60B |
Dividend Yield | 3.02% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Ferrari (RACE) trades at $412.26, up 1.22% on the day, near its pivot point of $412. The stock exhibits strong bullish momentum in moving averages and has beaten earnings estimates for three consecutive quarters. Revenue and net income have grown steadily, with 2025 revenue reaching $7.15B and net income $1.60B, though valuation ratios like a P/E of 38.45 are elevated. Recent news highlights robust demand, particularly for vehicle personalization, and the company raised its 2026 guidance following a strong Q2.
The outlook remains positive given strong fundamentals, bullish analyst sentiment, and raised guidance, but risks include high valuation multiples, potential economic sensitivity, and execution challenges with new models like the Luce EV. The consensus price target of $462.67 suggests ~12% upside, supported by institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
